Imatinib mesylate in advanced dermatofibrosarcoma protuberans: Pooled analysis of two phase II clinical trials

Journal of Clinical Oncology

Volumn 28, Issue 10, 2010, Pages 1772-1779

  Rutkowski, Piotr ^a   Van Glabbeke, Martine ^a   Rankin, Cathryn J ^a   Ruka, Wlodzimierz ^a   Rubin, Brian P ^a   Debiec Rychter, Maria ^a   Lazar, Alexander ^a   Gelderblom, Hans ^a   Sciot, Raf ^a   Lopez Terrada, Dolores ^a   Hohenberger, Peter ^a   Van Oosterom, Allan T ^a   Schuetze, Scott M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER SURGERY; CHEMOTHERAPY INDUCED EMESIS; DERMATOFIBROSARCOMA PROTUBERANS; DIARRHEA; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; HEAD AND NECK DISEASE; HEAD AND NECK EDEMA; HUMAN; HUMAN TISSUE; HYPERTENSION; LEUKOPENIA; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; VISCERAL EDEMA; CLINICAL TRIAL; DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; PHASE 2 CLINICAL TRIAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; DERMATOFIBROSARCOMA; DRUG ADMINISTRATION SCHEDULE; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES;

EID: 77950469922     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.7899     Document Type: Article

References (66)

1. Chang CK, Jacobs IA, Salti GI: Outcomes of surgery for dermatofibrosarcoma protuberans. Eur J Surg Oncol 30:341-345, 2004 (Pubitemid 38425655)
2. Laskin WB: Dermatofibrosarcoma protuberans. Ca Cancer J Clin 42:116-125, 1992
3. Mentzel T, Beham A, Katenkamp D, et al: Fibrosarcomatous ("high-grade") dermatofibrosarcoma protuberans: Clinicopathological and immunohistochemical study of 41 cases with emphasis on prognostic significance. Am J Surg Pathol 22:576-587, 1998 (Pubitemid 28213745)
4. Bowne WB, Antonescu CR, Leung DHY, et al: Dermatofibrosarcoma protuberans: A clinicopathological analysis of patients treated and followed at a single institution. Cancer 88:2711-2720, 2000 (Pubitemid 30417931)
5. Lal P, Sharma R, Mohan H, et al: Dermatofibrosarcoma protuberans metastasizing to lymph nodes: A case report and review of literature. J Surg Oncol 72:178-180, 1999
6. Diaz-Cascajo C, Weyers W, Bornego L, et al: Dermatofibrosarcoma protuberans with fibrosarcomatous areas: A clinico-pathologic and immunohistochemical study four cases. Am J Dermatopathol 19:562-567, 1997 (Pubitemid 27512405)
7. Kimmel Z, Ratner D, Kim JYS, et al: Peripheral excision margins for dermatofibrosarcoma protuberans: A meta-analysis of spatial data. Ann Surg Oncol 14:2113-2120, 2007 (Pubitemid 46988248)
8. Gloster HM Jr, Harris KR, Roenigk RK: A comparison between Mohs micrographic surgery and a wide surgical excision for the treatment of dermatofibrosarcoma protuberans. J Am Acad Dermatol 35:82-87, 1996 (Pubitemid 26231329)
9. Barnes L, Coleman JA Jr, Johnson JT: Dermatofibrosarcoma protuberans of the head and neck. Arch Otolaryngol 110:398-404, 1984 (Pubitemid 14109491)
10. Roses DF, Valensi Q, LaTrenta G, et al: Surgical treatment of dermatofibrosarcoma protuberans. Surg Gynecol Obstet 162:449-452, 1986 (Pubitemid 16026861)
11. Rutgers EJ, Kroon BB, Albus-Lutter CE, et al: Dermatofibrosarcoma protuberans: Treatment and prognosis. Eur J Surg Oncol 18:241-248, 1992
12. Koh CK, Ho CB, Bury HPR, et al: Dermatofibrosarcoma protuberans. Int J Dermatol 34:256-260, 1995
13. Stojadinovic A, Karpoff HM, Antonescu CR, et al: Dermatofibrosarcoma protuberans of the head and neck. Ann Surg Oncol 7:696-704, 2000
14. Ratner D, Thomas CO, Johnson TM, et al: Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans: Results of a multiinstitutional series with analysis of the extent of microscopic spread. J Am Acad Dermatol 37:600-613, 1997 (Pubitemid 27446732)
15. DuBay D, Cimmino V, Lowe L, et al: Low recurrence rate after surgery for dermatofibrosarcoma protuberans: A multidisciplinary approach from a single institution. Cancer 100:1008-1016, 2004 (Pubitemid 38222862)
16. Dawes KW, Hanke CW: Dermatofibrosarcoma protuberans treated with Mohs micrographic surgery: Cure rates and surgical margins. Dermatol Surg 22:530-534, 1996 (Pubitemid 26200108)
17. Wacker J, Khan-Durani B, Hartschuh W: Modified Mohs micrographic surgery in the therapy of dermatofibrosarcoma protuberans: Analysis of 22 patients. Ann Surg Oncol 11:438-444, 2004 (Pubitemid 40486756)
18. Mendenhall WM, Zlotecki RA, Scarborough MT: Dermatofibrosarcoma protuberans. Cancer 101:2503-2508, 2004 (Pubitemid 39532278)
19. Khatri VP, Galante JM, Bold RJ, et al: Dermatofibrosarcoma protuberans: Reappraisal of wide local excision and impact of inadequate initial treatment. Ann Surg Oncol 10:1118-1122, 2003 (Pubitemid 40486838)
20. Fiore M, Miceli R, Mussi C, et al: Dermatofibrosarcoma protuberans treated at a single institution: A surgical disease with a high cure rate. J Clin Oncol 23:7669-7675, 2005 (Pubitemid 46291832)
21. Suit H, Spiro I, Mankin HJ, et al: Radiation in management of patients with dermatofibrosarcoma protuberans. J Clin Oncol 14:2365-2369, 1996 (Pubitemid 26264889)
22. Ballo MT, Zagars GK, Pisters P, et al: The role of radiation therapy in the management of dermatofibrosarcoma protuberans. Int J Radiat Oncol Biol Phys 40:823-827, 1998 (Pubitemid 28150799)
23. Haas RL, Keus RB, Loftus BM, et al: The role of radiotherapy in the local management of dermatofibrosarcoma protuberans: Soft Tissue Tumors Working Group. Eur J Cancer 33:1055-1060, 1997 (Pubitemid 27310781)
24. Pedeutour F, Coindre J-M, Sozzi G, et al: Supernumerary ring chromosomes containing chromosome 17 sequences: A specific feature of dermatofibrosarcoma protuberans? Cancer Genet Cytogenet 76:1-9, 1994
25. Pedeutour F, Simon M-P, Minoletti F, et al: Ring 22 chromosomes in dermatofibrosarcoma protuberans are low-level amplifiers of chromosome 17 and 22 sequences. Cancer Res 55:2400-2403, 1995
26. Pedeutour F, Lacour JP, Perrin C, et al: Another case of t(17;22)(q22;q13) in an infantile dermatofibrosarcoma protuberans. Cancer Genet Cytogenet 89:175-176, 1996 (Pubitemid 26286760)
27. Pedeutour F, Simon MP, Minoletti F, et al: Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: A new tumor-associated chromosome rearrangement. Cytogenet Cell Genet 72:171-174, 1996 (Pubitemid 26080105)
28. Kiuru-Kuhlefelt S, El-Rifai W, Fanburg-Smith J, et al: Concomitant DNA copy number amplification at 17q and 22q in dermatofibrosarcoma protuberans. Cytogenet Cell Genet 92:192-195, 2001 (Pubitemid 32641992)
29. Linn SC, West RB, Pollack JR, et al: Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans. Am J Pathol 163:2383-2395, 2003 (Pubitemid 37466479)
30. Sandberg AA, Bridge JA: Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: Dermatofibrosarcoma protuberans and giant cell fibroblastoma. Cancer Genet Cytogenet 140:1-12, 2003 (Pubitemid 36110633)
31. Simon M-P, Navarro M, Roux D, et al: Structural and functional analysis of a chimeric protein COL1A1-PDGFB generated by the translocation t(17;22)(q22;q13.1) in dermatofibrosarcoma protuberans (DP). Oncogene 20:2965-2975, 2001 (Pubitemid 33027764)
32. Naeem R, Lux ML, Huang S-F, et al: Ring chromosomes in dermatofibrosarcoma protuberans are composed of interspersed sequences from chromosomes 17 and 22. Am J Pathol 147:1553-1558, 1995
33. Patel KU, Szabo SS, Hernandez VS, et al: Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. Hum Pathol 39:184-193, 2008
34. Kerob D, Pedeutour F, Leboeuf C, et al: Value of cytogenetic analysis in the treatment of dermatofibrosarcoma protuberans. J Clin Oncol 26:1757-1759, 2008
35. Wang J, Morimitsu Y, Okamoto S, et al: COL1A1-PDGFB fusion transcripts in fibrosarcomatous areas of six dermatofibrosarcoma protuberans. J Mol Diagn 2:47-52, 2000
36. Simon M-P, Navarro M, Roux D, et al: Transforming properties of chimerical protein COL1A1-PDGFB generated by dermatofibrosarcoma protuberans-associated translocation t(17; 22)(q22;q13.1). Cancer Genet Cytogenet 128:82, 2001
37. Shimizu A, O'Brien KP, Sjöblom T, et al: The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGFBB. Cancer Res 59:3719-3723, 1999 (Pubitemid 29381878)
38. Sjöblom T, Shimizu A, O'Brien KP, et al: Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 61:5778-5783, 2001 (Pubitemid 32769094)
39. Shmookler BM, Enzinger FM, Weiss SW: Giant cell fibroblastoma: A juvenile form of dermatofibrosarcoma protuberans. Cancer 64:2154-2161, 1989 (Pubitemid 19280419)
40. Dal Cin P, de Wever I, Brock P, et al: Cytogenetic and immunohistochemical evidence that giant cell fibroblastoma is related to dermatofibrosarcoma protuberans. Genes Chromosomes Cancer 15:73-75, 1996 (Pubitemid 26018460)
41. O'Brien KP, Seroussi E, Dal Cin P, et al: Various regions within the alpha-helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant-cell fibroblastomas. Genes Chromosomes Cancer 23:187-193, 1998 (Pubitemid 28402346)
42. Terrier-Lacombe MJ, Guillou L, Maire G, et al: Dermatofibrosarcoma protuberans, giant cell fibroblastoma, and hybrid lesions in children: Clinicopathologic comparative analysis of 28 cases with molecular data - A study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol 27:27-39, 2003 (Pubitemid 36014896)
43. Greco A, Fusetti L, Villa R, et al: Transforming activity of the chimeric sequence formed by the fusion of collagen gene COL1A1 and the platelet derived growth factor b-chain gene in dermatofibrosarcoma protuberans. Oncogene 17:1313-1319, 1998 (Pubitemid 28446172)
44. Maki RG, Awan RA, Dixon RH, et al: Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 100:623-626, 2002 (Pubitemid 34832970)
45. Rubin BP, Schuetze SM, Eary JF, et al: Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 20:3586-3591, 2002 (Pubitemid 34983217)
46. McArthur GA, Demetri GD, van Oosterom AT, et al: Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 23:866-873, 2005 (Pubitemid 46224187)
47. Verweij J, Casali PG, Zalcberg J, et al: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 364:1127-1134, 2004 (Pubitemid 39296599)
48. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000 (Pubitemid 30099779)
49. Blanke CD, Rankin C, Demetri GD, et al: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626-632, 2008 (Pubitemid 351264358)
50. Buchdunger E, Ciotfi CL, Law N, et al: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139-145, 2000
51. van Oosterom AT, Judson I, Verweij J, et al: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358:1421-1423, 2001 (Pubitemid 33055745)
52. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002 (Pubitemid 34879334)
53. O'Brien SG, Guilhot F, Larson RA, et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004, 2003 (Pubitemid 36302244)
54. Greco A, Roccato E, Miranda C, et al: Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGF-beta rearrangement. Int J Cancer 92:354-360, 2001 (Pubitemid 32249711)
55. Pedeutour F, Coindre JM, Nicolo G, et al: Response of metastatic dermatofibrosarcoma protuberans to imatinib mesylate. Proc Am Soc Clin Oncol 23:830, 2003 (abstr 3334)
56. Ruka W, Falkowski S, Wudarska J, et al: The partial response of lung metastases arising from dermatofibrosarcoma after one month of imatinib therapy: A case report. Nowotwory J Oncol 53:165-168, 2003 (Pubitemid 36604183)
57. Labropoulos SV, Fletcher JA, Oliveira AM, et al: Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. Anticancer Drugs 16:461-466, 2005 (Pubitemid 40434613)
58. Mizutani K, Tamada Y, Hara K, et al: Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans. Br J Dermatol 151:235-237, 2004 (Pubitemid 39061309)
59. Baars A, Pinedo HM: Good response to treatment with the selective tyrosine-kinase inhibitor imatinib in a patient with metastatic dermatofibrosarcoma protuberans. Ned Tijdschr Geneeskd 147:2072-2076, 2003 (Pubitemid 37295194)
60. Price VE, Fletcher JA, Zielenska M, et al: Imatinib mesylate: An attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans. Pediatr Blood Cancer 44:511-515, 2005 (Pubitemid 40614501)
61. Heinrich MC, Joensuu H, Demetri GD, et al: Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinibsensitive tyrosine kinases. Clin Cancer Res 14:2717-2725, 2008
62. Gronchi A, Stacchiotti S, Pedeutour F, et al: Response to imatinib mesylate (IM) in fibrosarcoma (FS) arising in dermatofibrosarcoma protuberans (DFSP). J Clin Oncol 26:576s, 2008 (suppl; abstr 10593)
63. McArthur G: Molecularly targeted treatment for dermatofibrosarcoma protuberans. Semin Oncol 31:30-36, 2004
64. Lebbé C, Kerob D, Porcher R, et al: Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: Results of a multicentric phase II study on 25 patients. J Clin Oncol 25:18s, 2007 (suppl; abstr 10032)
65. West RB, Rubin BP, Miller MA, et al: A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A 103:690-695, 2006 (Pubitemid 43153087)
66. Blay JY, El Sayadi H, Thiesse P, et al: Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann Oncol 19:821-822, 2008 (Pubitemid 351461057)